{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:42:02Z","timestamp":1788871322272,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":2527,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Dendreon Corporation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1093\/annonc\/mds216","type":"journal-article","created":{"date-parts":[[2012,7,24]],"date-time":"2012-07-24T20:50:28Z","timestamp":1343163028000},"page":"31-38","source":"Crossref","is-referenced-by-count":43,"title":["Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer"],"prefix":"10.1016","volume":"24","author":[{"given":"T.B.","family":"Dorff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.D.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds216_bb0010","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1634\/theoncologist.9-5-571","article-title":"Adjuvant analgesics in cancer pain management","volume":"9","author":"Lussier","year":"2004","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mds216_bb0015","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids\u2014new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1093\/annonc\/mds216_bb0020","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1200\/JCO.1989.7.5.590","article-title":"Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response","volume":"7","author":"Tannock","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds216_bb0025","first-page":"751","article-title":"Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study","volume":"69","author":"Bruera","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"10.1093\/annonc\/mds216_bb0030","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/1097-0142(197406)33:6<1607::AID-CNCR2820330620>3.0.CO;2-V","article-title":"Corticosteroid therapy of preterminal gastrointestinal cancer","volume":"33","author":"Moertel","year":"1974","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds216_bb0035","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds216_bb0040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2165\/00002018-199411030-00003","article-title":"The risks and benefits of corticosteroids in advanced cancer","volume":"11","author":"Twycross","year":"1994","journal-title":"Drug Saf"},{"key":"10.1093\/annonc\/mds216_bb0045","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF02571300","article-title":"Corticosteroid toxicity in neuro-oncology patients","volume":"5","author":"Weissman","year":"1987","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mds216_bb0050","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1212\/WNL.41.8.1235","article-title":"Steroid-induced weakness in patients with primary brain tumors","volume":"41","author":"Dropcho","year":"1991","journal-title":"Neurology"},{"key":"10.1093\/annonc\/mds216_bb0055","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/clinids\/11.6.954","article-title":"Risk of infectious complications in patients taking glucocorticosteroids","volume":"11","author":"Stuck","year":"1989","journal-title":"Rev Infect Dis"},{"key":"10.1093\/annonc\/mds216_bb0060","unstructured":"Bridgewater, NJsanofi-aventis U.S., LLCJevtana [package insert] June 2010"},{"key":"10.1093\/annonc\/mds216_bb0065","unstructured":"Bridgewater, NJsanofi-aventis U.S., LLCTaxotere [package insert] May 2010"},{"key":"10.1093\/annonc\/mds216_bb0070","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/pgmj.59.697.702","article-title":"Corticosteroids in terminal cancer\u2014a prospective analysis of current practice","volume":"59","author":"Hanks","year":"1983","journal-title":"Postgrad Med J"},{"key":"10.1093\/annonc\/mds216_bb0075","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4158\/EP.12.4.358","article-title":"Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients","volume":"12","author":"Donihi","year":"2006","journal-title":"Endocr Pract"},{"key":"10.1093\/annonc\/mds216_bb0080","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/1097-0142(20001215)89:12<2570::AID-CNCR9>3.0.CO;2-H","article-title":"Low doses of oral dexamethasone for hormone-refractory prostate carcinoma","volume":"89","author":"Nishimura","year":"2000","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds216_bb0085","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0090-4295(98)00149-6","article-title":"Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer","volume":"52","author":"Sartor","year":"1998","journal-title":"Urology"},{"issue":"Suppl. 16","key":"10.1093\/annonc\/mds216_bb0090","article-title":"Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy","volume":"23","author":"Vardy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds216_bb0095","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/annonc\/mdl347","article-title":"Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis","volume":"18","author":"Grunberg","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds216_bb0100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","article-title":"Mechanisms involved in the side effects of glucocorticoids","volume":"96","author":"Sch\u00e4cke","year":"2002","journal-title":"Pharmacol Ther"},{"key":"10.1093\/annonc\/mds216_bb0105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00005792-197801000-00002","article-title":"Aseptic necrosis of bone following renal transplantation: experience in 194 transplant recipients and review of the literature","volume":"57","author":"Ibels","year":"1978","journal-title":"Medicine"},{"key":"10.1093\/annonc\/mds216_bb0110","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/bmj.284.6312.333","article-title":"Avascular necrosis of bone after high doses of dexamethasone during neurosurgery","volume":"284","author":"McCluskey","year":"1982","journal-title":"Br Med J"},{"key":"10.1093\/annonc\/mds216_bb0115","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0039-6257(86)90077-9","article-title":"Corticosteroid-induced cataracts","volume":"31","author":"Urban","year":"1986","journal-title":"Surv Ophthalmol"},{"key":"10.1093\/annonc\/mds216_bb0120","doi-asserted-by":"crossref","first-page":"211","DOI":"10.6004\/jnccn.2010.0014","article-title":"Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer","volume":"8","author":"Saylor","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1093\/annonc\/mds216_bb0125","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds216_bb0130","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds216_bb0135","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1521-690X(03)00053-8","article-title":"Cortisol and the renal handling of electrolytes: role in glucocorticoid-induced hypertension and bone disease","volume":"17","author":"Ferrari","year":"2003","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mds216_bb0140","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/bmj.307.6903.519","article-title":"Steroid osteoporosis: a pragmatic approach is needed while prospective trials are awaited","volume":"307","author":"Spector","year":"1993","journal-title":"Br Med J"},{"key":"10.1093\/annonc\/mds216_bb0145","first-page":"433","article-title":"Osteonecrosis caused by combination chemotherapy","volume":"1","author":"No author","year":"1982","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds216_bb0150","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mds216_bb0155","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1096\/fj.01-0891fje","article-title":"Effects of altered glucocorticoid sensitivity in the T-cell lineage on thymocyte and T-cell homeostasis","volume":"16","author":"Pazirandeh","year":"2002","journal-title":"FASEB J"},{"key":"10.1093\/annonc\/mds216_bb0160","unstructured":"Horsham, PaJanssen Biotech, Inc.Zytiga [package insert] April 2011"},{"key":"10.1093\/annonc\/mds216_bb0165","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1023\/A:1012258723075","article-title":"Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer","volume":"12","author":"Beer","year":"2001","journal-title":"Ann Oncol"},{"issue":"Suppl. 4s","key":"10.1093\/annonc\/mds216_bb0170","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0093-7754(01)90149-6","article-title":"Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate","volume":"28","author":"Berry","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mds216_bb0175","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1200\/JCO.2006.06.8197","article-title":"Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators","volume":"25","author":"Beer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds216_bb0180","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2004.05.074","article-title":"Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer","volume":"22","author":"Dahut","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds216_bb0185","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1093\/annonc\/mds216_bb0190","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/jama.1985.03350400097029","article-title":"Reversible adrenal insufficiency induced by ketoconazole","volume":"253","author":"Tucker","year":"1985","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mds216_bb0195","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1398-9995.1997.tb00968.x","article-title":"Suppression of the immune system by oral glucocorticoid therapy in bronchial asthma","volume":"52","author":"Oehling","year":"1997","journal-title":"Allergy"},{"key":"10.1093\/annonc\/mds216_bb0200","unstructured":"E Cha L Fong. Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol 10.1200\/JCO.2010.34.5025"},{"key":"10.1093\/annonc\/mds216_bb0205","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1200\/JCO.2004.06.037","article-title":"Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)","volume":"22","author":"Small","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds216_bb0210","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds216_bb0215","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1093\/annonc\/mds216_bb0220","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2223\/JPED.1773","article-title":"Withdrawal from glucocorticosteroid therapy: clinical practice recommendations","volume":"84","author":"Alves","year":"2008","journal-title":"J Pediatr"},{"key":"10.1093\/annonc\/mds216_bb0225","unstructured":"NCCN Guidelines for Treatment of Cancer by Site: Prostate Cancer, V.4.2011, 21 June 2011 http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp"},{"key":"10.1093\/annonc\/mds216_bb0230","series-title":"Guidelines on Prostate Cancer","first-page":"68","volume":"53","author":"Heidenreich","year":"2008"},{"key":"10.1093\/annonc\/mds216_bb0235","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1200\/JCO.1999.17.8.2506","article-title":"Hydrocortisone with or without mitoxantrone in men with hormone-resistant prostate cancer: results of the cancer and leukemia group B 9182 study","volume":"17","author":"Kantoff","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds216_bb0240","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds216_bb0245","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3322\/canjclin.55.5.300","article-title":"Advances in prostate cancer chemotherapy: a new era begins","volume":"55","author":"Pienta","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mds216_bb0250","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"New Engl J Med"},{"issue":"suppl.","key":"10.1093\/annonc\/mds216_bb0255","first-page":"15s","article-title":"Median time to progression in chemotherapy (chemo)-naive patients with castration resistant prostate cancer (CRPC) treated with abiraterone acetate and low-dose prednisone (Pred)","volume":"28","author":"Ryan","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds216_bb0260","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.2741\/2441","article-title":"Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer","volume":"12","author":"Aragon-Ching","year":"2007","journal-title":"Front Biosci"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419370292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419370292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/1\/31\/5622471\/mds216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T03:23:16Z","timestamp":1624504996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419370292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0923753419370292"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds216","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}